Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bioavailability and feasibility of subcutaneous 5-fluorouracil

M M Borner1, J Kneer, C Crevoisier

  • 1Institut für Medizinische Onkologie, Universität Bern, Switzerland.

British Journal of Cancer
|September 1, 1993
PubMed
Summary

Subcutaneous (s.c.) 5-fluorouracil (5-FU) offers a well-tolerated alternative to intravenous (i.v.) infusion, demonstrating high bioavailability. This method may provide a safe and economical option for cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sexual cues alter working memory performance and brain processing in men with compulsive sexual behavior.

NeuroImage. Clinical·2020
Same author

An Exploratory Study on the Central Nervous Correlates of Sexual Excitation and Sexual Inhibition.

Journal of sex research·2018
Same author

Approach and Avoidance Tendencies Toward Picture Stimuli of (Pre-)Pubescent Children and Adults: An Investigation in Pedophilic and Nonpedophilic Samples.

Sexual abuse : a journal of research and treatment·2017
Same author

Fear, Pain, Denial, and Spiritual Experiences in Dying Processes.

The American journal of hospice & palliative care·2017
Same author

The Range of Neurological Complications in Chikungunya Fever.

Neurocritical care·2017
Same author

Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices.

European journal of cancer care·2017

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Delivery

Background:

  • Continuous intravenous (i.v.) 5-fluorouracil (5-FU) infusion shows superior efficacy but incurs higher costs and risks like thromboembolism and infection.
  • Subcutaneous (s.c.) administration presents a potential alternative to overcome i.v. infusion limitations.

Purpose of the Study:

  • To assess the feasibility and bioavailability of subcutaneous 5-FU.
  • To evaluate the local tolerance of prolonged s.c. 5-FU administration.

Main Methods:

  • Eight advanced cancer patients received 250 mg 5-FU via 90-min i.v. or s.c. infusion.
  • Three patients underwent 24-h continuous s.c. infusion of 930-1,000 mg m-2 5-FU.
  • Plasma concentration-time curves and local tolerance were monitored.

Related Experiment Videos

Main Results:

  • Mean s.c. 5-FU bioavailability was 0.89 ± 0.23, with plasma levels comparable to i.v. infusion.
  • No local side effects were observed during short-term s.c. infusion.
  • One patient experienced skin pigmentation at the s.c. site, a reaction also seen with i.v. infusion.

Conclusions:

  • Subcutaneous 5-FU demonstrates high bioavailability and good local tolerance at studied doses.
  • Prolonged s.c. 5-FU infusion warrants further investigation as a safe and economical alternative to i.v. administration.